NEWAMSTERDAM PHARMA CO NV (NAMS) Stock Price, Forecast & Analysis
USA - NASDAQ:NAMS - NL00150012L7 - Common Stock
NAMS Key Statistics, Chart & Performance
The current stock price of NAMS is 37.05 USD. In the past month the price increased by 12.26%. In the past year, price increased by 53.61%.
NAMS Latest News, Press Relases and Analysis
NAMS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B | ||
| INCY | INCYTE CORP | 16.39 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.03 | 15.35B |
Related stock screener links
About NAMS
Company Profile
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 68 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
Company Info
NEWAMSTERDAM PHARMA CO NV
Gooimeer 2-35
Naarden NOORD-HOLLAND NL
Employees: 68
Phone: 31352062971
NEWAMSTERDAM PHARMA CO NV / NAMS FAQ
What does NAMS do?
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 68 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.
Can you provide the latest stock price for NEWAMSTERDAM PHARMA CO NV?
The current stock price of NAMS is 37.05 USD. The price decreased by -2.83% in the last trading session.
Does NAMS stock pay dividends?
NAMS does not pay a dividend.
How is the ChartMill rating for NEWAMSTERDAM PHARMA CO NV?
NAMS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Who owns NEWAMSTERDAM PHARMA CO NV?
You can find the ownership structure of NEWAMSTERDAM PHARMA CO NV (NAMS) on the Ownership tab.
What is the Short Interest ratio of NEWAMSTERDAM PHARMA CO NV (NAMS) stock?
The outstanding short interest for NEWAMSTERDAM PHARMA CO NV (NAMS) is 7.18% of its float.
NAMS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NAMS. When comparing the yearly performance of all stocks, NAMS is one of the better performing stocks in the market, outperforming 93.03% of all stocks.
NAMS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NAMS Forecast & Estimates
19 analysts have analysed NAMS and the average price target is 43.86 USD. This implies a price increase of 18.38% is expected in the next year compared to the current price of 37.05.